{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:16:29Z","timestamp":1686215789928},"reference-count":34,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2018,12,2]]},"DOI":"10.1080\/17474086.2018.1537778","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T07:21:25Z","timestamp":1539933685000},"page":"911-914","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Optimal frontline management of mantle cell lymphoma: can we agree?"],"prefix":"10.1080","volume":"11","author":[{"given":"Catherine","family":"Tang","sequence":"first","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"issue":"10044","key":"CIT0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine O","year":"2016","journal-title":"Lancet"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.634"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119115"},{"key":"CIT0012","unstructured":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission. [cited 2018 Sep 10]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03267433."},{"key":"CIT0013","unstructured":"ASCT After a Rituximab\/Ibrutinib\/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma. [cited 2018 Sep 10]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02858258."},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e19548"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.03.001"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.162"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510441103"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628792"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30018-8"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30185-5"},{"key":"CIT0032","unstructured":"A Study of the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma. [cited 2018 Sep 10]. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT01776840."},{"issue":"15","key":"CIT0033","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel MJ","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2018.1537778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T10:30:36Z","timestamp":1598697036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2018.1537778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,2]]}},"alternative-id":["10.1080\/17474086.2018.1537778"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2018.1537778","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}